Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C18H29N3O5.ClH |
| Molecular Weight | 403.901 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN(C)C(=O)OC1=CC(=CC(OC(=O)N(C)C)=C1)C(O)CNC(C)(C)C
InChI
InChIKey=LBARATORRVNNQM-UHFFFAOYSA-N
InChI=1S/C18H29N3O5.ClH/c1-18(2,3)19-11-15(22)12-8-13(25-16(23)20(4)5)10-14(9-12)26-17(24)21(6)7;/h8-10,15,19,22H,11H2,1-7H3;1H
DescriptionCurator's Comment: Description was created based on several sources, including
https://www.medicines.org.uk/emc/medicine/9574 | http://www.meppo.com/pdf/drugs/2596-BAMBEC-ORAL-SOLUTION-1427211370.pdf | https://www.ncbi.nlm.nih.gov/pubmed/2906603
Curator's Comment: Description was created based on several sources, including
https://www.medicines.org.uk/emc/medicine/9574 | http://www.meppo.com/pdf/drugs/2596-BAMBEC-ORAL-SOLUTION-1427211370.pdf | https://www.ncbi.nlm.nih.gov/pubmed/2906603
Bambuterol is an active precursor of the selective beta2-adrenergic agonist terbutaline. Bambuterol is the bis-N,N-dimethyl-carbamate of terbutaline.
Bambuterol is a remarkably selective and potent inhibitor of cholinesterase. BAMBEC (Bambuterol hydrochloride) oral solution or tablets are indicated for the management of asthma, bronchospasm and/or reversible airways obstruction.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL210 |
|||
Target ID: CHEMBL1914 |
17.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | BAMBEC Approved UseBAMBEC (Bambuterol hydrochloride) oral solution or tablets are indicated for the management of asthma, bronchospasm and/or reversible airways obstruction. |
|||
| Primary | BAMBEC Approved UseBAMBEC (Bambuterol hydrochloride) oral solution or tablets are indicated for the management of asthma, bronchospasm and/or reversible airways obstruction. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| New lipophilic terbutaline ester prodrugs with long effect duration. | 1984 Jan |
|
| Tremor in healthy volunteers after bambuterol and terbutaline CR-tablets. | 1993 |
|
| Bambuterol and terbutaline in human cerebrospinal fluid and plasma. | 1993 |
|
| Therapeutic equivalence between bambuterol, 10 mg once daily, and terbutaline controlled release, 5 mg twice daily, in mild to moderate asthma. | 1993 Nov |
|
| Risk of non-fatal cardiac failure and ischaemic heart disease with long acting beta 2 agonists. | 1998 Jul |
|
| Can oral beta2 agonists cause heart failure? | 1998 Oct 3 |
|
| Oral bambuterol compared to inhaled salmeterol in patients with partially reversible chronic obstructive pulmonary disease. | 1999 Jan |
|
| Cholinesterases: new roles in brain function and in Alzheimer's disease. | 2003 Apr |
|
| Effects of acetylcholinesterase and butyrylcholinesterase inhibition on breathing in mice adapted or not to reduced acetylcholinesterase. | 2005 Jan |
|
| Stereoselective inhibition of human, mouse, and horse cholinesterases by bambuterol enantiomers. | 2008 Sep 25 |
|
| Influence of differential expression of acetylcholinesterase in brain and muscle on respiration. | 2009 Jan 1 |
Patents
Sample Use Guides
BAMBEC (Bambuterol hydrochloride) Tablets 10 mg. The recommended starting doses are 10 mg–20 mg. The 10 mg dose may be increased to 20 mg if necessary after 1–2 weeks, depending on the clinical effect. In patients who have previously tolerated beta2-agonists well, the recommended starting dose, as well as maintenance dose, is 20 mg.
BAMBEC (Bambuterol hydrochloride) oral solution 1mg/ml. The recommended initial dose is 10mg (10ml). The dose may be increased to 20mg (20ml) after 1-2 weeks, depending on the clinical effect. In patients who previously have tolerated oral beta2-agonists well, the recommended initial dose is 20mg (20ml).
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
54765
Created by
admin on Fri Dec 15 17:18:28 GMT 2023 , Edited by admin on Fri Dec 15 17:18:28 GMT 2023
|
PRIMARY | |||
|
DB01408
Created by
admin on Fri Dec 15 17:18:28 GMT 2023 , Edited by admin on Fri Dec 15 17:18:28 GMT 2023
|
PRIMARY | |||
|
DTXSID8045515
Created by
admin on Fri Dec 15 17:18:28 GMT 2023 , Edited by admin on Fri Dec 15 17:18:28 GMT 2023
|
PRIMARY | |||
|
81732-46-9
Created by
admin on Fri Dec 15 17:18:28 GMT 2023 , Edited by admin on Fri Dec 15 17:18:28 GMT 2023
|
PRIMARY | |||
|
786Q84QZ3F
Created by
admin on Fri Dec 15 17:18:28 GMT 2023 , Edited by admin on Fri Dec 15 17:18:28 GMT 2023
|
PRIMARY | |||
|
100000092785
Created by
admin on Fri Dec 15 17:18:28 GMT 2023 , Edited by admin on Fri Dec 15 17:18:28 GMT 2023
|
PRIMARY | |||
|
235862
Created by
admin on Fri Dec 15 17:18:28 GMT 2023 , Edited by admin on Fri Dec 15 17:18:28 GMT 2023
|
PRIMARY | RxNorm | ||
|
59167
Created by
admin on Fri Dec 15 17:18:28 GMT 2023 , Edited by admin on Fri Dec 15 17:18:28 GMT 2023
|
PRIMARY | |||
|
758916
Created by
admin on Fri Dec 15 17:18:28 GMT 2023 , Edited by admin on Fri Dec 15 17:18:28 GMT 2023
|
PRIMARY | |||
|
C047766
Created by
admin on Fri Dec 15 17:18:28 GMT 2023 , Edited by admin on Fri Dec 15 17:18:28 GMT 2023
|
PRIMARY | |||
|
m2216
Created by
admin on Fri Dec 15 17:18:28 GMT 2023 , Edited by admin on Fri Dec 15 17:18:28 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB00659MIG
Created by
admin on Fri Dec 15 17:18:28 GMT 2023 , Edited by admin on Fri Dec 15 17:18:28 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
